This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's How Much You'd Have If You Invested $1000 in Veracyte a Decade Ago
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
Should You Continue to Hold Bio-Rad Stock in Your Portfolio?
by Zacks Equity Research
BIO continues to attract investors' attention due to its robust performance in the ddPCR platform.
Is This the Right Time to Hold ALGN Stock in Your Portfolio?
by Zacks Equity Research
Align Technology continues to attract investors' confidence thanks to its share gains in the malocclusion market and strategic deals.
Is Quest Diagnostics Stock Worth Holding Onto Right Now?
by Zacks Equity Research
Strong momentum in Advanced Diagnostics and strategic acquisitions continues to attract investors to DGX.
National Vision Stock Rises 28.2% YTD: Will the Rally Continue?
by Zacks Equity Research
EYE's strength in its largest brand and actions to achieve a healthier store fleet position the stock favorably.
Veracyte (VCYT) Up 0.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Veracyte (VCYT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Wall Street Analysts Believe Veracyte (VCYT) Could Rally 35.05%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Veracyte (VCYT) points to a 35.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Is This the Right Time to Hold Integra Stock in Your Portfolio?
by Zacks Equity Research
IART stays on investors' radar courtesy of its strong prospects in the CSS segment and international growth.
GMED Stock Jumps 41.8% in a Year: What's Behind the Rally?
by Zacks Equity Research
Globus Medical's robust musculoskeletal offerings and synergies from the NuVasive merger are fueling its stock gains.
Should You Hold Globus Medical Stock in Your Portfolio Now?
by Zacks Equity Research
GMED stays on investors' radar due to its high NuVasive-merger synergies and solid Musculoskeletal prospects.
New Product Launches Benefit GMED Stock Amid Macro Issues
by Zacks Equity Research
Globus Medical currently awaits a strong cadence of product launches throughout the Musculoskeletal portfolio in the coming months of 2025.
Should You Retain IDEXX Stock in Your Portfolio for Now?
by Zacks Equity Research
IDXX stays on investors' radar due to the strength of its CAG Diagnostics business.
Veracyte Stock Surges 45.6% in a Year: What's Driving the Rally?
by Zacks Equity Research
Strength in VCYT's Afirma and Decipher tests continues to draw investors' attention.
Is it the Right Time to Hold Alcon Stock in Your Portfolio Now?
by Zacks Equity Research
ALC stays on investors' radar due to its Surgical arm performance and contributions from new products.
Should You Continue to Retain STERIS Stock in Your Portfolio Now?
by Zacks Equity Research
Investors continue to keep an eye on STE due to its promising Healthcare arm and AST segment's prospects.
Top 3 Medical Instruments Industry Stocks to Ride the GenAI Boom
by Urmimala Biswas
FMS, MASI and VCYT from the Zacks Medical Instruments industry are worth buying based on genAI adoption, strategic developments and strong fundamentals. Yet, geopolitical complications and wage and supply issues mar the prospects.
Veracyte Stock Falls Despite Q4 Earnings and Revenue Beat
by Zacks Equity Research
VCYT registers robust growth from its market-leading Decipher Prostate and Afirma tests.
Veracyte (VCYT) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Veracyte (VCYT) delivered earnings and revenue surprises of 24.14% and 1.60%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
ILMN Stock Might Rise From Collaboration With Broad Clinical Labs
by Zacks Equity Research
Illumina Collaborates with Broad Clinical Labs to set the standard for scalable single-cell research and accelerate discovery in areas such as disease modeling and drug development.
Is Veracyte Stock a Good Addition to Your Portfolio Right Now?
by Zacks Equity Research
VCYT stays on investors radar due to the strong performance of the Afirma and Decipher franchises.
Should Edwards Lifesciences Stock Remain in Your Portfolio Now?
by Zacks Equity Research
EW stock is on investors' radars due to the promising structural heart opportunities following the divestment of the Critical Care arm.
Expanding Diabetes Business Supports ABT Stock, FX Issues Stay
by Zacks Equity Research
Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.
Is it the Right Time to Hold EYE Stock in Your Portfolio Now?
by Zacks Equity Research
National Vision continues to draw investors' attention with its strategic transformation efforts, while positive industry trends should favor its growth.
Should You Hold IDEXX Stock in Your Portfolio for Now?
by Zacks Equity Research
IDEXX's robust strength in the CAG Diagnostics business and strong global performance are highly promising.
BIO Stock Might Rise Following the Offer to Acquire Stilla
by Zacks Equity Research
Bio-Rad offers to acquire all equity interests of Stilla Technology. The acquisition is expected to complement Bio-Rad's existing digital PCR portfolio.